Avastin, or Bevacizumab, has been shown to increase survival from bowel cancer in around ten to 15 per cent of patients, but it has been impossible to predict who will benefit. Avastin works by targeting and blocking the VEGF-A protein, two major forms of which are VEGF165 and VEGF165b. VEGF165 helps cancers to grow new blood vessels, so they can get food and oxygen from the blood - all cancers need a blood supply to be able to survive and grow. Its sister protein, VEGF165b, has the opposite effect and acts as a brake on this growth...
More...
More...